Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
OBJECTIVE
To report the acute and late toxicities of patients with high-risk localized prostate cancer treated using a concomitant hypofractionated, intensity-modulated radiotherapy boost combined with long-term androgen deprivation therapy.


METHODS
A prospective Phase I-II study of patients with any of the following: clinical Stage T3 disease, prostate-specific antigen level ≥ 20 ng/mL, or Gleason score 8-10. A dose of 45 Gy (1.8 Gy/fraction) was delivered to the pelvic lymph nodes with a concomitant 22.5 Gy prostate intensity-modulated radiotherapy boost, to a total of 67.5 Gy (2.7 Gy/fraction) in 25 fractions within 5 weeks. Image guidance was performed using three gold seed fiducials. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, and Radiation Therapy Oncology Group late morbidity scores were used to assess the acute and late toxicities, respectively. Biochemical failure was determined using the Phoenix definition.


RESULTS
A total of 97 patients were treated and followed up for a median of 39 months, with 88% having a minimum of 24 months of follow-up. The maximal toxicity scores were recorded. The grade of acute gastrointestinal toxicity was Grade 0 in 4%, 1 in 59%, and 2 in 37%. The grade of acute urinary toxicity was Grade 0 in 8%, 1 in 50%, 2 in 39%, and 3 in 4%. The grade of late gastrointestinal toxicity was Grade 0 in 54%, 1 in 40%, and 2 in 7%. No Grade 3 or greater late gastrointestinal toxicities developed. The grade of late urinary toxicity was Grade 0 in 82%, 1 in 9%, 2 in 5%, 3 in 3%, and 4 in 1% (1 patient). All severe toxicities (Grade 3 or greater) had resolved at the last follow-up visit. The 4-year biochemical disease-free survival rate was 90.5%.


CONCLUSIONS
A hypofractionated intensity-modulated radiotherapy boost delivering 67.5 Gy in 25 fractions within 5 weeks combined with pelvic nodal radiotherapy and long-term androgen deprivation therapy was well tolerated, with low rates of severe toxicity. The biochemical control rate at early follow-up has been promising. Additional follow-up is needed to determine the long-term biochemical control and prostate biopsy results.
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Harvey
H
Quon
Patrick C F
PC
Cheung
D Andrew
DA
Loblaw
Gerard
G
Morton
Geordi
G
Pang
Ewa
E
Szumacher
Cyril
C
Danjoux
Richard
R
Choo
Gillian
G
Thomas
Alex
A
Kiss
Alexandre
A
Mamedov
Andrea
A
Deabreu
D000368:Aged; D019583:Dose Fractionation, Radiation; D005270:Femur Head / Q000000981:diagnostic imaging / Q000528:radiation effects; D057918:Fiducial Markers; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D058958:Organs at Risk / Q000000981:diagnostic imaging / Q000528:radiation effects; D011446:Prospective Studies; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000473:pathology*; D011859:Radiography; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects* / Q000379:methods; D012007:Rectum / Q000000981:diagnostic imaging / Q000528:radiation effects; D001743:Urinary Bladder / Q000000981:diagnostic imaging / Q000528:radiation effects
D017430:Prostate-Specific Antigen